A wide range of aberrant expression of myeloid antigens including CD13 and CD33 in B-ALL and T-ALL cases reported in both eastern and western literature.13,17,22,23 While in present study CD13 (29.8%) was the most common aberrant myeloid marker followed by CD15 (20.3%), and CD 33 (17.2%) in B-ALL. The gene discussed is CD33; the disease is acute lymphoblastic leukemia.